The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

被引：252
作者：
Wilke, R. A. [1 ,2 ]
Ramsey, L. B. [3 ]
Johnson, S. G. [4 ,5 ]
Maxwell, W. D. [6 ]
McLeod, H. L. [7 ]
Voora, D. [8 ]
Krauss, R. M. [9 ]
Roden, D. M. [1 ,2 ]
Feng, Q. [1 ,2 ]
Cooper-DeHoff, R. M. [10 ,11 ]
Gong, L. [12 ]
Klein, T. E. [12 ,13 ]
Wadelius, M. [14 ]
Niemi, M. [15 ,16 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Oates Inst Expt Therapeut, Nashville, TN USA
[2] Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Nashville, TN USA
[3] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[4] Univ Colorado, Dept Pharm, Skaggs Sch Pharm & Pharmaceut Sci, Denver, CO 80202 USA
[5] Kaiser Permanente Colorado, Clin Pharm Serv, Denver, CO USA
[6] S Carolina Coll Pharm, Dept Clin Pharm & Outcomes Sci, Columbia, SC USA
[7] Univ N Carolina, Dept Pharm, Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC USA
[8] Duke Univ, Dept Med, Inst Genome Sci & Policy, Durham, NC USA
[9] Childrens Hosp Oakland, Res Inst, Dept Med, Oakland, CA 94609 USA
[10] Univ Florida, Div Cardiovasc Med, Gainesville, FL USA
[11] Univ Florida, Ctr Pharmacogen, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
[12] Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA
[13] Stanford Univ, PharmGKB Pharmacogenet & Pharmacogen Knowledge Ba, Palo Alto, CA 94304 USA
[14] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[15] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland
[16] Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 92卷 / 01期
基金：
欧洲研究理事会; 美国国家卫生研究院; 瑞典研究理事会;
关键词：
RISK-FACTORS; OATP-C; PLASMA-CONCENTRATIONS; STATIN; PHARMACOKINETICS; VARIANTS; DRUG; RHABDOMYOLYSIS; SLCO1B1-ASTERISK-5; POLYMORPHISMS;
D O I：
10.1038/clpt.2012.57
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.
引用
收藏
页码：112 / 117
页数：6
相关论文
共 41 条
[1]   Statin-induced myopathy: a review and update [J].
Abd, Thura T. ;
Jacobson, Terry A. .
EXPERT OPINION ON DRUG SAFETY, 2011, 10 (03) :373-387
[2]   Gemfibrozil greatly increases plasma concentrations of cerivastatin [J].
Backman, JT ;
Kyrklund, C ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) :685-691
[3]   Plasma concentrations of active simvastatin acid are increased by gemfibrozil [J].
Backman, JT ;
Kyrklund, C ;
Kivistö, KT ;
Wang, JS ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :122-129
[4]  
Brunham LR., 2011, Pharmacogenomics J
[5]   Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis [J].
Buettner, Catherine ;
Rippberger, Matthew J. ;
Smith, Julie K. ;
Leveille, Suzanne G. ;
Davis, Roger B. ;
Mittleman, Murray A. .
AMERICAN JOURNAL OF MEDICINE, 2012, 125 (02) :176-182
[6]   Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial [J].
Bulbulia, R. ;
Bowman, L. ;
Wallendszus, K. ;
Parish, S. ;
Armitage, J. ;
Peto, R. ;
Collins, R. ;
Meade, T. ;
Sleight, P. ;
Armitage, J. ;
Parish, S. ;
Youngman, L. ;
Buxton, M. ;
de Bono, D. ;
George, C. ;
Fuller, J. ;
Keech, A. ;
Mansfi, A. ;
Pentecost, B. ;
Simpson, D. ;
Warlow, C. ;
McNamara, J. ;
O'Toole, L. ;
Doll, R. ;
Wilhelmsen, L. ;
Fox, K. M. ;
Hill, C. ;
Sandercock, P. .
LANCET, 2011, 378 (9808) :2013-2020
[7]   Effect of OATPIBI (SLCOIBI) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers [J].
Chung, JY ;
Cho, JY ;
Yu, KS ;
Kim, JR ;
Oh, DS ;
Jung, HR ;
Lim, KS ;
Moon, KH ;
Shin, SG ;
Jang, IJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) :342-350
[8]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[9]   Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial [J].
de Lemos, JA ;
Blazing, MA ;
Wiviott, SD ;
Lewis, EF ;
Fox, KAA ;
White, HD ;
Rouleau, JL ;
Pedersen, TR ;
Gardner, LH ;
Mukherjee, R ;
Ramsey, KE ;
Palmisano, J ;
Bilheimer, DW ;
Pfeffer, MA ;
Califf, RM ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11) :1307-1316
[10]   Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs [J].
Graham, DJ ;
Staffa, JA ;
Shatin, D ;
Andrade, SE ;
Schech, SD ;
La Grenade, L ;
Gurwitz, JH ;
Chan, KA ;
Goodman, MJ ;
Platt, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2585-2590
12345